Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females

Inclusion Criteria:

• Subjects must be willing and able to provide written informed consent (for adults)or assent (for adolescents <18 years of age) and comply with all study procedures,prohibitions, restrictions, and scheduled visits

• Subjects must be female, healthy, sexually active, postmenarcheal, premenopausal,and of childbearing potential, between 13 and 45 years of age (inclusive at the timeof screening) and at risk for pregnancy

• Note: Childbearing potential is defined as subjects who are ovulating,premenopausal, and not surgically sterile (ie, have not undergone hysterectomy,salpingectomy, or bilateral oophorectomy). Subjects that have undergoneunilateral oophorectomy will not be considered surgically sterile and may beincluded in the study

• Note: Only subjects 18 to 45 years of age (inclusive at the time of screening)are eligible for inclusion in Part B

• Subjects must be willing to have vaginal intercourse (with a genetically malepartner) throughout the Treatment Period (ie, during each medication cycle) withoutusing a secondary (eg, spermicides) or emergency method of contraception

• Subjects must have a BMI of 18 kg/m2 or higher

• Subjects must have a systolic blood pressure of 159 mmHg or lower and a diastolicblood pressure of 99 mmHg or lower

• Note: The median of 3 blood pressure measurements will be used for thiscriterion

• Note: Subjects are required to rest for 5 minutes prior to the first bloodpressure measurement and for 1 minute between subsequent measurements.Measurements done without appropriate preparation of the subject (excludingcaffeine use, smoking, or excessive physical activity) should not beconsidered, and the measurement should be repeated upon appropriate preparationof the subject

• Subjects must be regularly menstruating (with cycle length between 21 and 35 days)for at least 3 months prior to the signing of the Informed Consent Form

• Note: Breastfeeding women can be included 6 weeks after delivery irrespectiveof menstrual cycles post-delivery

• Subjects must agree to not use any secondary (eg, spermicides) or emergencycontraceptive methods during the study period

• Subjects must not be enrolled or plan to enroll in any other clinical study duringthe study period

• Subjects must be willing to use the study drug (LPRI-CF113) for 13 (28-day)medication cycles, and be willing to use the provided diary

• Subjects must generally be in good physical and mental health based on a medicalhistory and a physical examination performed by the Investigator at screening

Exclusion Criteria:

PART A:

• The subject is pregnant at the time of screening

• The subject has a desire to become pregnant at the time of screening

• Note: The subject will be asked if she has a desire for pregnancy at screening (and at each study visit). If a positive answer is given at screening, thesubject will be excluded

• The subject plans regular concomitant use of barrier contraceptive methods,spermicides, intrauterine device, other contraceptive measures, prohibitedmedications, and drugs contraindicated for study drug

• The subject has an abnormal and clinically significant finding on pelvic, breast, orultrasound examination at screening based on the judgment of the Investigator

• The subject has an abnormal and clinically significant finding on physicalexamination, clinical laboratory assessments (chemistry, hematology, urinalysis), or 12-lead ECG assessment based on the judgment of the Investigator

• The subject has had less than 3 menstrual cycles after discontinuing dosing of depotmedroxyprogesterone acetate (Depo-Provera®) or any combined injectable contraceptive (eg, Cyclofem®) prior to consent/assent. Those with spontaneous menses while oninjectable contraceptive will be considered for inclusion

• The subject has received any of the following:

• A progestin-releasing intra-uterine device or contraceptive implant within 2months prior to screening or

• A beta-human chorionic gonadotropin (β-hCG) or co-medication containing β-hCGwithin 1 month prior to screening

• The subject at the time of screening has a history of primary amenorrhea orsecondary amenorrhea (with or without known etiology)

• Note: Primary amenorrhea is defined as no menarche by 16 years of age withnormal secondary sexual characteristics

• Note: Secondary amenorrhea is defined as the absence of menses for 3 months inthe setting of previously normal (ie, regular) menstruation

• The subject has a current male sexual partner with a history of infertility,vasectomy, or bilateral orchiectomy

• The subject has an abnormal Pap smear finding of low-grade squamous intraepitheliallesion or higher at screening or 6 months prior to screening. Subjects <21 years ofage at screening do not require a Pap smear

• Note: Human papilloma virus (HPV) testing, by polymerase chain reaction (PCR),will be performed only in the case of atypical squamous cells of undeterminedsignificance (ASC-US). Subjects with ASC-US can be included if negative forhigh-risk HPV strains

• Note: A historical Pap smear may be used for eligibility if performed withinthe past 6 months with results available

• The subject has a history of uncontrolled medical illness (eg, the subject has anuncontrolled thyroid disorder and is not on a stable treatment regimen for 2 or moremonths)

• The subject has a history of jaundice while taking hormonal contraceptives

• The subject has a history of alcohol or substance use disorder within 12 monthsprior to screening. Alcohol abuse is defined as typical consumption of 14 or morealcoholic drinks weekly

• Note: One drink of alcohol is equivalent to ½ pint of beer (285 mL), 1 glass ofspirits (25 mL), or 1 glass of wine (125 mL)

• The subject has a history or current evidence of clinically significant psychiatricillness, such as major depression or schizophrenia, that in the opinion of theInvestigator contraindicates participation in the study

• The subject has surgical procedures scheduled to occur during the study that wouldpreclude use of contraceptives or require withdrawal of contraceptives

• The subject has a history of an inherited or acquired disorder that predisposes thesubject to venous or arterial thromboembolism (eg, factor V Leiden mutation,prothrombin mutation, presence of antiphospholipid antibodies)

• The subject has received an investigational product within 3 months prior toscreening

• The subject has a history of using or currently uses any medications known tointerfere with the efficacy of hormonal contraceptives, or other prohibitedmedications or products

• Medications known to reduce the efficacy of hormonal contraceptives:

• Barbiturates

• Bosentan

• Anticonvulsants (e.g., topiramate, phenytoin, carbamazepine, oxcarbazepine,felbamate, rufinamide)

• Primidone

• Rifampin

• Human immunodeficiency virus peptidase inhibitors (e.g., ritonavir, nelfinavir)

• Non-nucleoside reverse transcriptase inhibitors (e.g., nevirapine, efavirenz)

• Griseofulvin

• Products containing St. John's Wort (hypericum perforatum)

• Other prohibited medications or products:

• Rifabutin

• Aprepitant

• Hepatitis C treatments (eg, boceprevir, telaprevir)

• Azole antifungals (eg, fluconazole, itraconazole, ketoconazole, voriconazole)

• Macrolides (eg, clarithromycin, erythromycin)

• Verapamil

• Diltiazem

• Cyclosporine

• Lamotrigine

• Sex hormones

• Grapefruit juice

• The subject has a history of severe or critical Coronavirus Disease 2019 (COVID-19)or has been hospitalized for COVID-19 within 3 months prior to screening

• Note: Severe COVID-19 severity is defined as individuals who have SpO2 <94% onroom air at sea level, a PaO2/FiO2 <300 mmHg, a respiratory rate >30breaths/min, or lung infiltrates >50%

• Note: Critical COVID-19 severity is defined as individuals who have respiratoryfailure, septic shock, and/or multiple organ dysfunction

• The subject has any ongoing condition or history of medical illness that in theopinion of the Investigator may jeopardize the conduct of the study or impactscreening

• The subject is employed by the Sponsor, the Contract Research Organization (CRO), orthe clinical facility (permanent, temporary contract worker, or designee responsiblefor the conduct of the study), or is a family member (spouse, parent, sibling, orchild) of the Sponsor, CRO, or clinical facility employee

• The subject has a known contraindication or hypersensitivity to ingredients orexcipients of the study drug (LPRI-CF113)

• The subject has a history of or is currently being treated for any of the following:

• Renal insufficiency

• Hepatic insufficiency

• Adrenal insufficiency

• Venous thromboembolism (ie, deep vein thrombosis, pulmonary embolism)

• Arterial thromboembolism of cardiac origin (eg, valvular heart disease)

• Cerebral vascular disease

• Coronary artery disease

• Diabetic vasculopathy

• Headaches with focal neurological symptoms

• Major surgery requiring more than 7 days of immobilization within 3 monthsprior to screening

• Carcinoma of the breast

• Estrogen or progestin sensitive malignancies

• Abnormal vaginal bleeding in the 6 months prior to screening

• Cholestatic jaundice during pregnancy

• Liver tumor (benign or malignant)

• Active liver disease

• Rheumatoid arthritis

PART B:

• The subject is <18 years of age, inclusive

• The subject has a BMD Z-score of -1.5 at or lower at screening

• The subject has a history of low-trauma fracture (eg, fracture from a fall fromstanding height). This does not include fractures of the fingers, toes, or skull

• The subject has a history of medical conditions or procedures associated with lowBMD. This includes the following:

• Metabolic bone disease (eg, Paget's Disease of the bone, osteomalacia)

• Collagen vascular disease (eg, Marfan syndrome, Ehlers-Danlos syndrome,osteogenesis imperfecta)

• Malabsorptive disease (eg, inflammatory bowel disease, postgastrectomysyndrome)

• Bariatric surgery (except gastric banding)

• Abnormal bone mineral metabolism (eg, hypocalcemia/hypercalcemia,hypophosphatemia/hyperphosphatemia, hypomagnesemia)

• The subject has a history of chronic (3 or more months) use within 12 months ofscreening of the following medications known to increase BMD:

• Bisphosphonates

• Denosumab

• Teriparatide

• Abaloparatide

• Romosozumab

• Calcitonin

• Fluoride

• Strontium

• The subject has a history of chronic (3 or more months) use within 12 months ofscreening of the following medications known to decrease BMD:

• Glucocorticoids administered orally, intravenously, or by inhalation.

• Note: Subjects taking chronic oral or intravenous glucocorticoids (eg,prednisone >2.5 mg daily for 3 or more months) will have a washout period of 12months

• Depo-Provera.

• Note: Subjects using Depo-Provera for 2 or more years will be excluded

• Aromatase inhibitors within 2 years prior to screening

• Raloxifene within 2 years prior to screening

• Anticonvulsants (phenytoin, phenobarbital, carbamazepine, or valproate)

• Protease inhibitors

• Cyclosporine

• Heparin

• Warfarin

• Thiazolidinediones

• Sodium-glucose transporter protein 2 inhibitors

• Tricyclic antidepressants

• Proton pump inhibitors

• Selective serotonin reuptake inhibitors within 3 months prior to screening

• The subject has any of the following that may preclude accurate BMD measurement byDXA scan:

• History of lumbar spine surgery

• History of bilateral hip surgery

• Surgical placement of metallic implant (eg, nails, clips, screws, rods, pins,wires)

• Piercings that cannot be removed

• Weight or height that exceeds the limit of DXA scan table